Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

astrazeneca limited - chadox1-s 100 gvp/ml (gvp = giga viral particles; equivalent to not less than to 5.0 x 10^8 infectious units per ml);  ;  ;   - solution for injection - active: chadox1-s 100 gvp/ml (gvp = giga viral particles; equivalent to not less than to 5.0 x 10^8 infectious units per ml)       excipient: disodium edetate dihydrate ethanol histidine histidine hydrochloride monohydrate magnesium chloride hexahydrate polysorbate 80 sodium chloride sucrose water for injection - covid-19 vaccine astrazeneca is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. the use of this vaccine should be in accordance with official recommendations.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - ad26.cov2.s 100 gvp/ml (gvp = giga viral particles; equivalent to not less than to 8.92 log10 infectious units per dose) - suspension for injection - active: ad26.cov2.s 100 gvp/ml (gvp = giga viral particles; equivalent to not less than to 8.92 log10 infectious units per dose) excipient: citric acid monohydrate ethanol hydrochloric acid hydroxypropyl-beta-cyclodextrin polysorbate 80 sodium chloride sodium citrate dihydrate sodium hydroxide water for injection - covid-19 vaccine janssen has provisional consent for the indication below: active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. the use of this vaccine should be in accordance with official recommendations.

Malaizija - angļu - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

johnson & johnson sdn bhd - rad26.cov2-s -

Malaizija - angļu - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - cx-024414 mrna -

Singapūra - angļu - HSA (Health Sciences Authority)

biontech pharmaceuticals asia pacific pte. ltd. - raxtozinameran - injection - raxtozinameran 10 μg/dose

Singapūra - angļu - HSA (Health Sciences Authority)

biontech pharmaceuticals asia pacific pte. ltd. - raxtozinameran - injection - raxtozinameran 30 μg/dose

Malaizija - angļu - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

astrazeneca sdn. bhd. - azd1222 -

Malaizija - angļu - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - tozinameran -

Malaizija - angļu - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - tozinameran -

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - tozinameran 0.1 mg/ml equivalent to 10 µg/0.2ml dose after dilution;  ;  ;  ;   - concentrate for injection - 0.1 mg/ml - active: tozinameran 0.1 mg/ml equivalent to 10 µg/0.2ml dose after dilution         excipient: 1,2-distearoyl-sn-glycero-3-phosphocholine alc-0159 alc-0315 cholesterol sucrose trometamol trometamol hydrochloride water for injection - active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2, in children aged 5 to 11 years. the use of this vaccine should be in accordance with official recommendations.